Schedule of advances from customers |
| |
As of December 31, 2022 | | |
As of December 31, 2021 | |
Advances from customers(1) | |
| 434,890 | | |
| 471,788 | |
| |
$ | 434,890 | | |
$ | 471,788 | |
(1) | On
October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen
Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5
million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7
and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation
Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a
clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount
of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial
that lasts at least one month. |
|